Command Palette

Search for a command to run...

Preprint WatchMildNovember 7th, 2026

Druggable CSNK2A1-MeCP2 regulatory axis links Okur-Chung neurodevelopmental syndrome with MECP2-related disorders

Anderson, A. G.; Chamakuri, S.; Meyer-Schuman, R.; Chu, E. H.-Y.; Revelli, J.-P.; Kim, J.; Zaghlula, M.; Veeraragavan, S.; Young, D. W.; Zoghbi, H. Y.

A CSNK2A1-driven regulatory axis stabilizes MeCP2, and the authors report that the axis is druggable using a novel CSNK2A1 inhibitor in human cells and by targeting Csnk2a1 in a MECP2 duplication mouse model.

Mild contradiction

1 prior failure

One documented clinical failure (Phase 1 or 2) overlaps with the claimed mechanism.

This preprint proposes CSNK2A1 inhibition as a route to tuning MeCP2 abundance in neurodevelopmental disease. Claidex holds one CSNK2A1 failure, silmitasertib-cx-4945-csnk2a1-shh-medulloblastoma-pbtc-053-phase1-2-translational-mismatch, where a casein kinase 2 inhibitor with clear preclinical rationale did not translate in SHH medulloblastoma. The relevant caution is dose and tissue exposure rather than target plausibility. MeCP2 abundance is tightly bounded in both directions, so a therapy that works by partially destabilizing a stabilizing kinase needs a therapeutic window demonstrated in vivo, and the prior clinical attempt at CK2 inhibition did not establish that such a window exists at tolerated exposures.

Abstract excerpt

The brain is exquisitely sensitive to methyl-CpG-binding protein 2 (MeCP2) abundance. Too little causes Rett syndrome (RTT), too much causes MECP2 duplication syndrome (MDS), and in both, severity tracks with the amount of functional MeCP2. Even modest deviations are detrimental, yet how MeCP2 abundance is controlled remains poorly understood. Using genome-wide CRISPR knockout screens, we identified hundreds of proteins regulating MeCP2, revealing a casein kinase 2 alpha 1 (CSNK2A1)-driven regulatory axis stabilizing MeCP2. We show this axis is druggable and therapeutically relevant, using a novel CSNK2A1 inhibitor in human cells and targeting Csnk2a1 in an MDS mouse model. We further connect CSNK2A1-MeCP2 regulatory disruption to Okur-Chung neurodevelopmental syndrome (OCNDS), caused by mutations in CSNK2A1, finding ~50% less hippocampal MeCP2 in an OCNDS mouse model. Together, these data identify a druggable regulatory axis modulating MeCP2 and implicate MeCP2 dysregulation in the molecular pathogenesis of OCNDS and potentially other neurodevelopmental disorders.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.